These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9292911)

  • 41. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
    Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
    Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Basic therapies in cystic fibrosis. Does standard therapy work?
    Marshall BC; Samuelson WM
    Clin Chest Med; 1998 Sep; 19(3):487-504, vi. PubMed ID: 9759551
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overnight delivery of hypertonic saline by nasal cannula aerosol for cystic fibrosis.
    Corcoran TE; Godovchik JE; Donn KH; Busick DR; Goralski J; Locke LW; Markovetz MR; Myerburg MM; Muthukrishnan A; Weber L; Lacy RT; Pilewski JM
    Pediatr Pulmonol; 2017 Sep; 52(9):1142-1149. PubMed ID: 28737262
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
    McCoy K; Hamilton S; Johnson C
    Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of airway inflammation in cystic fibrosis.
    Konstan MW
    Curr Opin Pulm Med; 1996 Nov; 2(6):452-6. PubMed ID: 9363184
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular strategies for therapy of cystic fibrosis.
    Wagner JA; Chao AC; Gardner P
    Annu Rev Pharmacol Toxicol; 1995; 35():257-76. PubMed ID: 7598494
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The expanding armamentarium of drugs to aid sputum clearance: how should they be used to optimize care?
    Bilton D; Stanford G
    Curr Opin Pulm Med; 2014 Nov; 20(6):601-6. PubMed ID: 25221855
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lung inflammation as a therapeutic target in cystic fibrosis.
    Koehler DR; Downey GP; Sweezey NB; Tanswell AK; Hu J
    Am J Respir Cell Mol Biol; 2004 Oct; 31(4):377-81. PubMed ID: 15381503
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of dornase alfa in the treatment of cystic fibrosis.
    Cramer GW; Bosso JA
    Ann Pharmacother; 1996 Jun; 30(6):656-61. PubMed ID: 8792953
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease.
    Moore PJ; Tarran R
    Expert Opin Ther Targets; 2018 Aug; 22(8):687-701. PubMed ID: 30028216
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively?
    Tiddens HA; Donaldson SH; Rosenfeld M; Paré PD
    Pediatr Pulmonol; 2010 Feb; 45(2):107-17. PubMed ID: 20082341
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nutrition in cystic fibrosis.
    Matel JL; Milla CE
    Semin Respir Crit Care Med; 2009 Oct; 30(5):579-86. PubMed ID: 19760545
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The epithelium as a target for therapy in cystic fibrosis.
    Thelin WR; Boucher RC
    Curr Opin Pharmacol; 2007 Jun; 7(3):290-5. PubMed ID: 17475561
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease.
    Matsui H; Grubb BR; Tarran R; Randell SH; Gatzy JT; Davis CW; Boucher RC
    Cell; 1998 Dec; 95(7):1005-15. PubMed ID: 9875854
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cystic fibrosis: the role of the small airways.
    Ratjen F
    J Aerosol Med Pulm Drug Deliv; 2012 Oct; 25(5):261-4. PubMed ID: 22857153
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhalation-based therapies in the treatment of cystic fibrosis.
    Harris CE; Wilmott RW
    Curr Opin Pediatr; 1994 Jun; 6(3):234-8. PubMed ID: 8061731
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis.
    Robinson M; Regnis JA; Bailey DL; King M; Bautovich GJ; Bye PT
    Am J Respir Crit Care Med; 1996 May; 153(5):1503-9. PubMed ID: 8630593
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.
    Goa KL; Lamb H
    Pharmacoeconomics; 1997 Sep; 12(3):409-22. PubMed ID: 10170464
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early cystic fibrosis lung disease: Role of airway surface dehydration and lessons from preventive rehydration therapies in mice.
    Mall MA; Graeber SY; Stahl M; Zhou-Suckow Z
    Int J Biochem Cell Biol; 2014 Jul; 52():174-9. PubMed ID: 24561284
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nebulised hypertonic saline for cystic fibrosis.
    Wark PA; McDonald V
    Cochrane Database Syst Rev; 2000; (2):CD001506. PubMed ID: 10796798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.